Drug Approval | December 21, 2024
USFDA approves Encorafenib plus Cetuximab and Chemo in BRAF V600E-positive mCRC
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Merck will record a pre-tax charge relating to the upfront payment of $588 million
The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery
The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
In the US, the compassionate use approvals are provided by FDA in the form of individual patient-specific expanded-access IND
Difluprednate Ophthalmic Emulsion, 0.05% is a topical corticosteroid that is indicated in the treatment of inflammation and pain associated with ocular surgery
Merck has also decided to end the favezelimab clinical development program
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
Kiran Mazumdar-Shaw received the award from Janak Kumar Mehta, President of ISQ and Chairman & Managing Director, TQM International
Subscribe To Our Newsletter & Stay Updated
